Design, Synthesis, and Pharmacology of New Triazole-Containing Quinolinones as CNS Active Agents.

Epilepsy and major depressive disorder are the two of the most common central nervous system (CNS) diseases. Clinicians and patients call for new antidepressants, antiseizure medicines, and in particular drugs for depression and epilepsy comorbidities. In this work, a dozen new triazole-quinolinones were designed, synthesized, and investigated as CNS active agents. All compounds reduced the immobility time significantly during the forced swim test (FST) in mice at the dosage of 50 mg/kg. Compounds 3f-3j gave superior performance over fluoxetine in the FST with more reductions of the immobility time. Compound 3g also reduced immobility time significantly in a tail suspension test (TST) at the dosage of 50 mg/kg, though its anti-immobility activity was inferior to that of fluoxetine. An open field test was carried out and it eliminated the false-positive possibility of 3g in the FST and TST, which complementarily supported the antidepressant activity of 3g. We also found that almost all compounds except 3k exhibited antiseizure activity in the maximal electroshock seizure (MES) model at 100 or 300 mg/kg. Compounds 3c, 3f, and 3g displayed the ED50 of 63.4, 78.9, and 84.9 mg/kg, and TD50 of 264.1, 253.5, and 439.9 mg/kg, respectively. ELISA assays proved that the mechanism for the antiseizure and antidepressant activities of compound 3g was via affecting the concentration of GABA in mice brain. The molecular docking study showed a good interaction between 3g and the amino acid residue of the GABAA receptor. Excellent drug-like properties and pharmacokinetic properties of compound 3a-l were also predicted by Discovery Studio. These findings provided a new skeleton to develop agents for the treatment of epilepsy and depression comorbidities.

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure.

PI3Kδ is a key mediator of B-cell receptor signaling and plays an important role in the pathogenesis of certain hematological malignancies, such as chronic lymphocytic leukemia. Idelalisib, which targets PI3Kδ specifically, is the first approved PI3K inhibitor for cancer therapy. Recently, we carried out virtual screening, cell-based assays, adapta kinase assays, and molecular dynamic analysis to discover novel PI3Kδ inhibitors and identified NSC348884 as a lead PI3Kδ inhibitor. NSC348884 had an excellent docking score, potent PI3Kδ-inhibitory activity, antitumor effects on various cancer cell lines, and a favorable binding mode with the active site of PI3Kδ. Moreover, through the structural modification of NSC348884, we further discovered comp#1, which forms H-bonds with both Val828 and Lys779 in the ATP binding pocket of PI3Kδ, with a more favorable conformation binding to PI3Kδ. In addition, we found that N1, N1, N2-trimethyl-N2-((6-methyl-1H-benzo[d]imidazol-2-yl) methyl) ethane-1,2-diamine might be a potential scaffold structure. Thus, the result of this study provides a far more efficient approach for discovering novel inhibitors targeting PI3Kδ.

Phosphatidylinositol 3-kinase ß and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.

Metastasis is the main cause of the lethality of prostate cancer. Class I phosphatidylinositol 3-kinases (PI3Ks), which contain 4 isoforms, α, ß, δ, and γ, are known to play important roles in cell growth, migration, invasion, and so on. However, the respective role of each PI3K isoform in cancer cell migration and invasion remains unknown. In a study that aimed to elucidate the respective role of the 4 PI3K isoforms, we investigated the change in migratory and invasive ability of DU145 cells after treatment with each PI3K isoform-specific inhibitor. Both migration and invasion of DU145 cells were potently blocked by each of the PI3Kß inhibitors (GSK2636771 and TGX221) and PI3Kδ inhibitors (CAL101 and IC87114) while not obviously affected by PI3Kα inhibitor BYL719 or PI3Kγ inhibitor AS252424. Furthermore, knocking down PI3Kß or PI3Kδ isoform led to a significant decrease in migration of DU145. The results suggest that PI3Kß and PI3Kδ play key roles in prostate cancer cell migration, while PI3Kα and PI3Kγ might be redundant. Oral administration of GSK2636771 (100 mg/kg) and CAL101 (30 mg/kg) inhibited tumor growth in bone, an experimental model by intratibia injection of DU145 cells, with improved bone structure and bone mineral density analyzed by micro-computed tomography. Tissue staining indicated reduction of metastatic DU145 cells and osteoclasts in the bones of GSK2636771- and CAL101-treated mice compared to the untreated group. In summary, our results indicated the distinct roles of 4 PI3K isoforms in the migration of prostate cancer DU145 cells, and they demonstrated the in vitro and in vivo antimetastatic effect of PI3K-isoform specific inhibitors, most of which are in clinical trials.-Zhang, Z., Liu, J., Wang, Y., Tan, X., Zhao, W., Xing, X., Qiu, Y., Wang, R., Jin, M., Fan, G., Zhang, P., Zhong, Y., Kong, D. Phosphatidylinositol 3-kinase ß and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.

SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.

BACKGROUND: Aberrant alternative splicing (AS) is a pervasive event during colorectal cancer (CRC) development. SF3B3 is a splicing factor component of U2 small nuclear ribonucleoproteins which are crucial for early stages of spliceosome assembly. The role of SF3B3 in CRC remains unknown. METHODS: SF3B3 expression in human CRCs was analyzed using publicly available CRC datasets, immunohistochemistry, qRT-PCR, and western blot. RNA-seq, RNA immunoprecipitation, and lipidomics were performed in SF3B3 knockdown or overexpressing CRC cell lines. CRC cell xenografts, patient-derived xenografts, patient-derived organoids, and orthotopic metastasis mouse models were utilized to determine the in vivo role of SF3B3 in CRC progression and metastasis. RESULTS: SF3B3 was upregulated in CRC samples and associated with poor survival. Inhibition of SF3B3 by RNA silencing suppressed the proliferation and metastasis of CRC cells in vitro and in vivo, characterized by mitochondria injury, increased reactive oxygen species (ROS), and apoptosis. Mechanistically, silencing of SF3B3 increased mTOR exon-skipped splicing, leading to the suppression of lipogenesis via mTOR-SREBF1-FASN signaling. The combination of SF3B3 shRNAs and mTOR inhibitors showed synergistic antitumor activity in patient-derived CRC organoids and xenografts. Importantly, we identified SF3B3 as a critical regulator of mTOR splicing and autophagy in multiple cancers. CONCLUSIONS: Our findings revealed that SF3B3 promoted CRC progression and metastasis by regulating mTOR alternative splicing and SREBF1-FASN-mediated lipogenesis, providing strong evidence to support SF3B3 as a druggable target for CRC therapy.

In vitro antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells.

Tumor metastasis is the main cause of lethality of prostate cancer, because conventional therapies like surgery and hormone treatment rarely work at this stage. Tumor cell migration, invasion and adhesion are necessary processes for metastasis. By providing nutrition and an escape route from the primary site, angiogenesis is also required for tumor metastasis. Phosphatidylinositol 3-kinases (PI3Ks) are well known to play important roles in tumorigenesis as well as metastasis. ZSTK474 is a specific PI3K inhibitor developed for solid tumor therapy. In the present report, antimetastatic activities of ZSTK474 were investigated in vitro by determining the effects on the main metastatic processes. ZSTK474 exhibited inhibitory effects on migration, invasion and adhesive ability of prostate cancer PC3 cells. Furthermore, ZSTK474 inhibited phosphorylation of Akt substrate-Girdin, and the secretion of matrix metalloproteinase (MMP), both of which were reported to be closely involved in migration and invasion. On the other hand, ZSTK474 inhibited the expression of HIF-1α and the secretion of vascular endothelial growth factor (VEGF), suggesting its potential antiangiogenic activity on PC3 cells. Moreover, we demonstrated the antiangiogenesis by determining the effect of ZSTK474-reduced VEGF on tube formation of human umbilical vein endothelial cells (HUVECs). In conclusion, ZSTK474 was demonstrated to have potential in vitro antimetastatic effects on PC3 cells via dual mechanisms: inhibition of metastatic processes including cell migration, invasion and adhesion, and antiangiogenesis via blockade of VEGF secretion.

Endobronchial Ultrasound Image Simulation for Image-Guided Bronchoscopy.

BACKGROUND/OBJECTIVE: Accurate disease diagnosis and staging are essential for patients suspected of having lung cancer. The state-of-the-art minimally invasive tools used by physicians to perform these operations are bronchoscopy, for navigating the lung airways, and endobronchial ultrasound (EBUS), for localizing suspect extraluminal cancer lesions. While new image-guided systems enable accurate bronchoscope navigation close to a lesion, no means exists for guiding the final EBUS localization of an extraluminal lesion. We propose an EBUS simulation method to assist with EBUS localization. METHODS: The method draws on a patient's chest computed-tomography (CT) scan to model the ultrasound signal propagation through the tissue media. The method, which is suitable for simulating EBUS images for both radial-probe and convex-probe EBUS devices, entails three steps: 1) image preprocessing, which generates a 2D CT equivalent of the EBUS scan plane; 2) EBUS scan-line computation, which models ultrasound transmission to map the CT plane into a preliminary simulated EBUS image; and 3) image post-processing, which increases realism by introducing simulated EBUS imaging effects and artifacts. RESULTS: Results show that the method produces simulated EBUS images that strongly resemble images generated live by a real device and compares favorably to an existing ultrasound simulation method. It also produces images at a rate greater than real time (i.e., 53 frames/sec). We also demonstrate a successful integration of the method into an image-guided EBUS bronchoscopy system. CONCLUSION/SIGNIFICANCE: The method is effective and practical for procedure planning/preview and follow-on live guidance of EBUS bronchoscopy.

Multimodal Registration for Image-Guided EBUS Bronchoscopy.

The state-of-the-art procedure for examining the lymph nodes in a lung cancer patient involves using an endobronchial ultrasound (EBUS) bronchoscope. The EBUS bronchoscope integrates two modalities into one device: (1) videobronchoscopy, which gives video images of the airway walls; and (2) convex-probe EBUS, which gives 2D fan-shaped views of extraluminal structures situated outside the airways. During the procedure, the physician first employs videobronchoscopy to navigate the device through the airways. Next, upon reaching a given node's approximate vicinity, the physician probes the airway walls using EBUS to localize the node. Due to the fact that lymph nodes lie beyond the airways, EBUS is essential for confirming a node's location. Unfortunately, it is well-documented that EBUS is difficult to use. In addition, while new image-guided bronchoscopy systems provide effective guidance for videobronchoscopic navigation, they offer no assistance for guiding EBUS localization. We propose a method for registering a patient's chest CT scan to live surgical EBUS views, thereby facilitating accurate image-guided EBUS bronchoscopy. The method entails an optimization process that registers CT-based virtual EBUS views to live EBUS probe views. Results using lung cancer patient data show that the method correctly registered 28/28 (100%) lymph nodes scanned by EBUS, with a mean registration time of 3.4 s. In addition, the mean position and direction errors of registered sites were 2.2 mm and 11.8∘, respectively. In addition, sensitivity studies show the method's robustness to parameter variations. Lastly, we demonstrate the method's use in an image-guided system designed for guiding both phases of EBUS bronchoscopy.

Design, Synthesis, and Evaluation of Anticonvulsant Activities of New Triazolopyrimidine Derivatives.

Epilepsy, a severe brain disease affecting a large population, is treated mainly by antiepileptic drugs (AEDs). However, toxicity, intolerance, and low efficiency of the available AEDs have prompted the continual attempts in the discovery of new AEDs. In this study, we discovered a skeleton of triazolopyrimidine for the development of new AEDs. The design, synthesis, in vivo anticonvulsant activity evaluation of triazolopyrimidines (3a-3i and 6a-6e), and pyrazolopyrimidines (4a-4i) are reported. We found that most triazolopyrimidines showed anticonvulsive activity in the maximal electroshock (MES) and pentetrazol (PTZ)-induced seizure models. On the contrary, pyrazolopyrimidines (4a-4i) showed weak or no protective effects. Among the tested derivatives, compound 6d, holding a median effective dose (ED50) of 15.8 and 14.1 mg/kg against MES and PTZ-induced seizures, respectively, was found to be the most potent one. Moreover, the protection index (PI) value of 6d was significantly higher than that of the available AEDs such as valproate, carbamazepine, and diazepam. The antiepileptic efficacy of compound 6d was also observed in the 3-mercaptopropionic acid and bicuculline-induced seizure models. Antagonistic effects of flumazenil and 3-MP for the anticonvulsive activity of 6d and also the radioligand-binding assay confirmed the involvement of GABA receptors, at least benzodiazepine (BZD) receptor, in the anticonvulsant activity of compound 6d. The docking study of compounds 4e and 6d with GABAA receptor confirmed and explained their affinity to the BZD receptors.

Antiproliferative effect of aaptamine on human chronic myeloid leukemia K562 cells.

We previously isolated aaptamine, a benzonaphthyridine alkaloid, from marine sponge Aaptos suberitoids. In this study, we investigated the anti-proliferative effect of aaptamine on chronic myeloid leukemia (CML) K562 cells. Aaptamine inhibited growth of K562 with a GI50 as 10 µM, and arrested cell cycle at G2/M phase. Western blot analysis indicated that aaptamine induced p21 expression in K562 cells. Moreover, p21 promoter was activated by aaptamine treatment in p21 transfected K562 cells. Since K562 is p53 negative, aaptamine was demonstrated to be a p53-independent p21 inducer in CML cells.

In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells.

BACKGROUND: The lethality of prostate cancer is mainly due to metastasis. Inhibition of metastasis is expected to be a promising approach for prostate cancer therapy. Phosphatidylinositol 3-kinase (PI3K)/Akt pathway is reported to be closely involved in cell growth, migration, etc. Objective: The study investigated the antimetastatic activities of pan-PI3K inhibitor ZSTK474 on DU145 cells. METHODS: 1. The In vitro effect of ZSTK474 on the migration, invasion and adhesion of DU145 cells was determined with Transwell migration assay and wound healing assay, Tranwell invasion assay and adhesion assay, respectively. 2. In vitro effect of ZSTK474 on the signal proteins in DU145 cells was determined with Western blot analysis and ELISA. 3. Moreover, the In vivo antimetastatic effect of ZSTK474 was evaluated with MicroCT and histology analysis. RESULTS: ZSTK474 potently attenuated the capability of migration, invasion and adhesion of DU145 cells, negatively regulated Girdin, Integrinß1 and matrix metalloproteinases (MMPs). In addition, the expression of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), which are known to be related to angiogenesis and metastasis, was also inhibited. Oral administration of ZSTK474 (200 mg/kg) ameliorated in vivo bone metastasis of DU145 cells, with improved bone structure and bone mineral density (BMD). Tissue staining indicated a reduction in metastatic DU145 cells and osteoclasts in the bones of ZSTK474-treated mice, compared with the non-treated group. CONCLUSION: Our result demonstrated the antimetastatic activity of ZSTK474 on prostate cancer DU145 cells, suggesting the potential application in prostate cancer patients.

Automation and optimization of liquid-phase microextraction by gas chromatography.

Several fully automated liquid-phase microextraction (LPME) techniques, including static headspace LPME (HS-LPME) (a drop of solvent is suspended at the tip of a microsyringe needle and exposed to the headspace of the sample solution), exposed dynamic HS-LPME (the solvent is exposed in the headspace of sample vial for different time, and then withdrawn into the barrel of the syringe. This procedure is repeated a number of times), unexposed dynamic HS-LPME (the solvent is moved inside the needle and the barrel of a syringe, and the gaseous sample is withdrawn into the barrel and then ejected), static direct-immersed LPME (DI-LPME) (a drop of solvent is suspended at the tip of a microsyringe needle and directly immersed into the sample solution), dynamic DI-LPME (the solvent is moved inside the needle and the barrel of a syringe, and the sample solution is withdrawn and ejected), and two phase hollow fiber-protected LPME (HF-LPME) (a hollow fiber is used to stabilize and protect the solvent), auto-performed with a commercial CTC CombiPal autosampler, are described in this paper. Critical experimental factors, including temperature, choice of extraction solvent, solvent volume, plunger movement rate, and extraction time were investigated. Among the three HS-LPME techniques that were evaluated, the exposed dynamic HS-LPME technique provided the best performance, compared to the unexposed dynamic HS-LPME and static HS-LPME approaches. For DI-LPME, the dynamic process can enhance the extraction efficiency and the achieved method precision is comparable with the static DI-LPME technique. The precision of the fully automated HF-LPME is quite acceptable (RSD values below 6.8%), and the concentration enrichment factors are better than the DI-LPME approaches. The fully automated LPME techniques are more accurate and more convenient, and the reproducibility achieved eliminates the need for an internal standard to improve the method precision.

Time-weighted average water sampling with a diffusion-based solid-phase microextraction device.

A new diffusion-based solid-phase microextraction (SPME) time-weighted average (TWA) field water sampling device was developed and investigated by field trial. The sampler is constructed with copper tube and caps and a commercial SPME fiber assembly. The device possesses all advantages of SPME; it is solvent-free, reusable, combines sampling, isolation and enrichment into one step, and the fiber can be directly injected into a gas chromatograph for analysis with a commercial SPME fiber holder, without further treatment. Field trials in Laurel Creek (Waterloo, Ont., Canada) and Hamilton Harbour (Hamilton, Ont., Canada) illustrated that the device is durable, easy to deploy, and the mass uptake of the device is independent of the face velocity. The device provides good precision [relative standard deviations (RSDs) are less than 20%] and the data obtained with this device are quite comparable to those obtained with the spot sampling method, which demonstrates that the newly developed SPME water sampling device is suitable for long-term monitoring of organic pollutants in water.

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers. Class I PI3Ks are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH of the inositol ring to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt and the downstream effectors like mammalian target of rapamycin (mTOR) to play key roles in carcinogenesis. Therefore, PI3K has become an important anticancer drug target, and currently there is very high interest in the pharmaceutical development of PI3K inhibitors. Idelalisib has been approved in USA and Europe as the first-in-class PI3K inhibitor for cancer therapy. Dozens of other PI3K inhibitors including BKM120 and ZSTK474 are being evaluated in clinical trials. Multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc. This review provides an introduction to PI3K and summarizes key advances in the development of PI3K inhibitors.

On-rod standardization technique for time-weighted average water sampling with a polydimethylsiloxane rod.

In this study, a polydimethylsiloxane (PDMS) rod was developed as a passive sampler, based on the solid-phase microextraction (SPME) technique. The on-rod standardization technique was applied to the PDMS rod passive sampler. Using the desorption of the pre-loaded standard on the PDMS rod to calibrate the absorption of the target analytes allows for the determination of the time-weighted average (TWA) concentrations of pollutants in the aqueous media. The PDMS rod passive sampler with the on-rod standardization technique was tested in the laboratory with a flow-through system and was subsequently applied to measure TWA concentrations of polycyclic aromatic hydrocarbons (PAHs) in the field (Hamilton Harbour, Hamilton, Ont., Canada). Both the laboratory and field experiments demonstrated that, with the on-rod standardization technique, the PDMS rod can be successfully used as a passive sampler for TWA water sampling in the field. The PDMS rod passive sampler benefits from the inherent advantages of the SPME approach: it incorporates sampling, isolation and enrichment into one step. The design of this system also addressed the additional needs for passive sampling techniques, providing an economical approach to field sampling that is also easy to deploy. Rather, with this approach, TWA concentrations of target analytes can be obtained by one sampler, and can be analyzed directly, with no further sample preparation treatment required.

In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.

Chronic myelogenous leukemia (CML) is a malignant hematological disorder mainly caused by the Bcr-Abl tyrosine kinase. While Bcr-Abl inhibitors including Imatinib showed antitumor efficacy on many CML patients, resistance was frequently reported in recent years. Therefore, novel drugs for CML are still expected. ZSTK474 is a specific phosphatidylinositol 3-kinase (PI3K) inhibitor that we identified. In the present study, the efficacy of ZSTK474, alone or in combination with Imatinib, on K562 CML cells as well as on its multidrug resistance counterpart K562/A02 cells, was investigated. ZSTK474 inhibited the cell proliferation with an IC50 of 4.69 µM for K562 and 7.57 µM for K562/A02 cells, respectively. Treatment by ZSTK474 resulted in cell cycle arrest in G1 phase, which might be associated with upregulation of p27, and downregulation of cyclin D1. ZSTK474 also inhibited phosphorylation of Akt and GSK-3ß, which might be involved in the effect on the above cell cycle-related proteins. Moreover, combination of ZSTK474 and Imatinib indicated synergistic effect on both cell lines. In conclusion, ZSTK474 exhibited antileukemia activity alone, and showed synergistic effect when combined with Imatinib, on CML K562 cells as well as the multidrug resistant ones, providing a potential therapeutic approach for CML patients.

Kinetic calibration using dominant pre-equilibrium desorption for on-site and in vivo sampling by solid-phase microextraction.

A new kinetic calibration was developed using dominant pre-equilibrium desorption by solid-phase microextracton. The calibration was based on isotropism between absorption and desorption, which was proved theoretically and experimentally in an aqueous solution and semisolid matrix. This approach allows for the calibration of absorption using desorption to compensate for matrix effects. Moreover, concentration profiles are initially proposed to verify isotropism between the absorption and desorption, while providing a linear approach to obtain time constants for the purpose of quantitative analysis. This linear approach is more convenient, robust, and accurate than the nonlinear version with the previously used time profiles. Furthermore, the target analytes are used as the internal standards; thus, radioactive or deuterated internal standards are not necessary. In addition, dominant pre-equilibrium desorption utilizes the pre-equilibrium approach and offers a shorter sample preparation time, which is typically suitable for in vivo sampling. This kinetic calibration method was successfully applied to prepare samples of polycyclic aromatic hydrocarbons in a flow-through system and in vivo pesticide sampling in a jade plant (Crassula ovata).

Preparation and application of in-fibre internal standardization solid-phase microextraction.

The in-fibre standardization method is a novel approach that has been developed for field sampling/sample preparation, in which an internal standard is pre-loaded onto a solid-phase microextraction (SPME) fibre for calibration of the extraction of target analytes in field samples. The same method can also be used for in-vial sample analysis. In this study, different techniques to load the standard to a non-porous SPME fibre were investigated. It was found that the appropriateness of the technique depends on the physical properties of the standards that are used for the analysis. Headspace extraction of the standard dissolved in pumping oil works well for volatile compounds. Conversely, headspace extraction of the pure standard is an effective approach for semi-volatile compounds. For compounds with low volatility, a syringe-fibre transfer method and direct extraction of the standard dissolved in a solvent exhibited a good reproducibility (<5% RSD). The main advantage of the approaches investigated in this study is that the standard generation vials can be reused for hundreds of analyses without exhibiting significant loss. Moreover, most of the standard loading processes studied can be performed automatically, which is efficient and precise. Finally, the standard loading technique and in-fibre standardization method were applied to a complex matrix (milk) and the results illustrated that the matrix effect can be effectively compensated for with this approach.

Time-weighted average water sampling in Lake Ontario with solid-phase microextraction passive samplers.

In this study, three types of solid-phase microextraction (SPME) passive samplers, including a fiber-retracted device, a polydimethylsiloxane (PDMS)-rod and a PDMS-membrane, were evaluated to determine the time weighted average (TWA) concentrations of polycyclic aromatic hydrocarbons (PAHs) in Hamilton Harbor (the western tip of Lake Ontario, ON, Canada). Field trials demonstrated that these types of SPME samplers are suitable for the long-term monitoring of organic pollutants in water. These samplers possess all of the advantages of SPME: they are solvent-free, sampling, extraction and concentration are combined into one step, and they can be directly injected into a gas chromatograph (GC) for analysis without further treatment. These samplers also address the additional needs of a passive sampling technique: they are economical, easy to deploy, and the TWA concentrations of target analytes can be obtained with one sampler. Moreover, the mass uptake of these samplers is independent of the face velocity, or the effect can be calibrated, which is desirable for long-term field sampling, especially when the convection conditions of the sampling environment are difficult to measure and calibrate. Among the three types of SPME samplers that were tested, the PDMS-membrane possesses the highest surface-to-volume ratio, which results in the highest sensitivity and mass uptake and the lowest detection level.

Kinetic calibration for automated headspace liquid-phase microextraction.

The kinetics of the absorption and desorption of analytes for headspace liquid-phase microextraction (HS-LPME) were studied. It was found that the desorption of analytes from the extraction phase into the sample matrix is isotropic to the absorption of the analytes from the sample matrix into the extraction phase under the same conditions. This therefore allows for the calibration of absorption using desorption. Calibration was accomplished by exposing the extraction phase, which contained a standard, to the sample matrix. The information from the desorption of the standard, such as time constant a, could be directly used to estimate the concentration of the target analyte in the sample matrix. This new kinetic calibration method for headspace LPME was successfully used to correct the matrix effects in the BTEX analysis of an orange juice sample. In this study, the headspace LPME techniques were successfully fully automated, for both static and dynamic methods, with the CTC CombiPal autosampler. All operations of headspace LPME, including sample transfer and agitation, filling of extraction solvent, exposing the solvent in the headspace, withdrawing the solvent to syringe and introducing the extraction phase into injector, were autoperformed by the CTC autosampler. The fully automated headspace LPME technique is more convenient and improved the precision and sensitivity of the method. This automated dynamic headspace LPME technique can be also used to obtain the distribution coefficient between the sample matrix (aqueous or another solution) and the extraction phase (1-octanol or another solvent). The distribution coefficient between 1-octanol and orange juice, at 25 degrees C, was obtained with this technique.